17beta-Oestradiol enhances aortic endothelium function and smooth muscle contraction in male spontaneously hypertensive rats. 2004

Chia-Hung Yen, and Ying-Tung Lau
Department of Physiology and Pharmacology, Chang Gung University College of Medicine, 259 Wen Hwa 1 Rd., Kwei-Shan, Taoyuan, Taiwan, Republic of China.

17beta-Oestradiol (E(2); oestrogen) is known to increase endothelium-dependent vasodilatation and NO (nitric oxide) production. It is also known to decrease the response of VSMCs (vascular smooth muscle cells) to vasoconstrictors in vitro. E(2) induces a decrease in age-related BP (blood pressure) development in MSHR (male spontaneously hypertensive rats). Whether this decrease is due to an effect on the endothelium or smooth muscle is unknown. To determine this effect, we examined the role of E(2) on vascular endothelium and smooth muscle separately. We treated MSHR with E(2) (2 mg x kg(-1) of body weight x week(-1)) for 5-7 weeks and then examined the vasoconstrictor response in the intact and denuded rings (with or without endothelium respectively). SBP (systolic BP) was measured weekly. Aortic cGMP and cAMP contents, aortic vasoconstrictor response, endothelium suppression of the vasoconstrictor response and basal NO release from aortic rings were all measured at the end of the study. We found that the age-related development of SBP in MSHR was decreased in E(2)-treated rats. The vascular response of denuded rings to a vasoconstrictor (phenylephrine and KCl) was increased in E(2)-treated rats; however, this phenomenon was masked in intact rings. The enhanced endothelial function appears to override the E(2)-increased smooth muscle vasoconstrictor response. Endothelium suppression, NO release and aortic cGMP content were all significantly higher in E(2)-treated rats than in controls. Thus our results suggest that E(2) improves endothelium function; furthermore, the accompanied NO/cGMP increase and the endothelium suppression may be associated with an E(2)-induced BP-lowering effect in MSHR.

UI MeSH Term Description Entries
D006973 Hypertension Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more. Blood Pressure, High,Blood Pressures, High,High Blood Pressure,High Blood Pressures
D008297 Male Males
D009119 Muscle Contraction A process leading to shortening and/or development of tension in muscle tissue. Muscle contraction occurs by a sliding filament mechanism whereby actin filaments slide inward among the myosin filaments. Inotropism,Muscular Contraction,Contraction, Muscle,Contraction, Muscular,Contractions, Muscle,Contractions, Muscular,Inotropisms,Muscle Contractions,Muscular Contractions
D009131 Muscle, Smooth, Vascular The nonstriated involuntary muscle tissue of blood vessels. Vascular Smooth Muscle,Muscle, Vascular Smooth,Muscles, Vascular Smooth,Smooth Muscle, Vascular,Smooth Muscles, Vascular,Vascular Smooth Muscles
D009566 Nitrates Inorganic or organic salts and esters of nitric acid. These compounds contain the NO3- radical. Nitrate
D009573 Nitrites Salts of nitrous acid or compounds containing the group NO2-. The inorganic nitrites of the type MNO2 (where M Nitrite
D011918 Rats, Inbred SHR A strain of Rattus norvegicus with elevated blood pressure used as a model for studying hypertension and stroke. Rats, Spontaneously Hypertensive,Rats, SHR,Inbred SHR Rat,Inbred SHR Rats,Rat, Inbred SHR,Rat, SHR,Rat, Spontaneously Hypertensive,SHR Rat,SHR Rat, Inbred,SHR Rats,SHR Rats, Inbred,Spontaneously Hypertensive Rat,Spontaneously Hypertensive Rats
D004730 Endothelium, Vascular Single pavement layer of cells which line the luminal surface of the entire vascular system and regulate the transport of macromolecules and blood components. Capillary Endothelium,Vascular Endothelium,Capillary Endotheliums,Endothelium, Capillary,Endotheliums, Capillary,Endotheliums, Vascular,Vascular Endotheliums
D004958 Estradiol The 17-beta-isomer of estradiol, an aromatized C18 steroid with hydroxyl group at 3-beta- and 17-beta-position. Estradiol-17-beta is the most potent form of mammalian estrogenic steroids. 17 beta-Estradiol,Estradiol-17 beta,Oestradiol,17 beta-Oestradiol,Aerodiol,Delestrogen,Estrace,Estraderm TTS,Estradiol Anhydrous,Estradiol Hemihydrate,Estradiol Hemihydrate, (17 alpha)-Isomer,Estradiol Monohydrate,Estradiol Valerate,Estradiol Valeriante,Estradiol, (+-)-Isomer,Estradiol, (-)-Isomer,Estradiol, (16 alpha,17 alpha)-Isomer,Estradiol, (16 alpha,17 beta)-Isomer,Estradiol, (17-alpha)-Isomer,Estradiol, (8 alpha,17 beta)-(+-)-Isomer,Estradiol, (8 alpha,17 beta)-Isomer,Estradiol, (9 beta,17 alpha)-Isomer,Estradiol, (9 beta,17 beta)-Isomer,Estradiol, Monosodium Salt,Estradiol, Sodium Salt,Estradiol-17 alpha,Estradiol-17beta,Ovocyclin,Progynon-Depot,Progynova,Vivelle,17 beta Estradiol,17 beta Oestradiol,Estradiol 17 alpha,Estradiol 17 beta,Estradiol 17beta,Progynon Depot
D006152 Cyclic GMP Guanosine cyclic 3',5'-(hydrogen phosphate). A guanine nucleotide containing one phosphate group which is esterified to the sugar moiety in both the 3'- and 5'-positions. It is a cellular regulatory agent and has been described as a second messenger. Its levels increase in response to a variety of hormones, including acetylcholine, insulin, and oxytocin and it has been found to activate specific protein kinases. (From Merck Index, 11th ed) Guanosine Cyclic 3',5'-Monophosphate,Guanosine Cyclic 3,5 Monophosphate,Guanosine Cyclic Monophosphate,Guanosine Cyclic-3',5'-Monophosphate,3',5'-Monophosphate, Guanosine Cyclic,Cyclic 3',5'-Monophosphate, Guanosine,Cyclic Monophosphate, Guanosine,Cyclic-3',5'-Monophosphate, Guanosine,GMP, Cyclic,Guanosine Cyclic 3',5' Monophosphate,Monophosphate, Guanosine Cyclic

Related Publications

Chia-Hung Yen, and Ying-Tung Lau
September 1979, Japanese heart journal,
Chia-Hung Yen, and Ying-Tung Lau
January 1987, Clinical and experimental hypertension. Part A, Theory and practice,
Chia-Hung Yen, and Ying-Tung Lau
February 1993, The American journal of physiology,
Chia-Hung Yen, and Ying-Tung Lau
February 2008, Journal of pharmacological sciences,
Chia-Hung Yen, and Ying-Tung Lau
March 1987, Biulleten' eksperimental'noi biologii i meditsiny,
Chia-Hung Yen, and Ying-Tung Lau
January 2002, Fiziolohichnyi zhurnal (Kiev, Ukraine : 1994),
Chia-Hung Yen, and Ying-Tung Lau
May 1975, The Journal of endocrinology,
Chia-Hung Yen, and Ying-Tung Lau
January 1995, Life sciences,
Copied contents to your clipboard!